Press release
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nThe first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant\n\n\nThis transplant builds on two successful UHeart transplants completed in 2022 and 2023\n\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nPlease replace the photo for release dated April 24, 2024 with the accompanying corrected photo.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424110823/en/A) Genetically modified source pig, 16 to 20 weeks old. B) The thymus is then explanted from the source genetically modified pig, and the thymic tissue is implanted under its kidney capsule. C) The thymus tissue matures under the kidney capsule for six to eight weeks. D) The UThymoKidney is procured and transplanted into human recipient. (Photo: Business Wire)\nThe release reads:\n\n\nUNITED THERAPEUTICS ANNOUNCES WORLD’S FIRST SUCCESSFUL XENOTHYMOKIDNEY TRANSPLANT\n\n\nThe first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant\n\n\nThis transplant builds on two successful UHeart transplants completed in 2022 and 2023\n\n\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024. This transplant represents several historic firsts for transplantation:\n\n\n- The first-ever transplant of a xenothymokidney into a living human recipient;\n- The first-ever combined mechanical heart pump and organ transplant; and\n- The first-ever xenotransplant into a living human using only FDA-approved immunosuppressive medicines\n\n\nThe transplant is the third xenotransplant using United Therapeutics’ xeno organs, following two successful UHeart™ transplants at the University of Maryland Medicine in 2022 and 2023.\n\n\nThe transplant was authorized by U.S. Food and Drug Administration (FDA) under the expanded access pathway and performed by surgeons at NYU Langone Health led by Robert Montgomery, M.D., DPhil. The patient, a 54-year-old woman from New Jersey, suffers from heart and kidney failure. The combination of several chronic medical conditions, coupled with a lack of available human organs f...